| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Gossamer Bio, Inc. | Director | Stock Option (Right to Buy) | 115,000 | 25 Jun 2025 | Direct | ||
| Magenta Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 20,000 | 28 Jun 2022 | Direct | ||
| Larimar Therapeutics, Inc. | Director | Stock Option (right to buy) | 8,300 | 12 May 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | 25 Jun 2025 | 1 | $0 | 4 | Director | 26 Jun 2025, 16:40 |
| GOSS | Gossamer Bio, Inc. | 06 Jun 2024 | 1 | $0 | 4 | Director | 06 Jun 2024, 21:57 |
| GOSS | Gossamer Bio, Inc. | 08 Jun 2023 | 1 | $0 | 4 | Director | 09 Jun 2023, 16:13 |
| DNTH | Magenta Therapeutics, Inc. | 28 Jun 2022 | 1 | $0 | 4 | Director | 30 Jun 2022, 18:37 |
| GOSS | Gossamer Bio, Inc. | 09 Jun 2022 | 1 | $0 | 4 | Director | 15 Jul 2022, 17:15 |
| GOSS | Gossamer Bio, Inc. | 09 Jun 2021 | 1 | $0 | 4 | Director | 10 Jun 2021, 19:54 |
| DNTH | Magenta Therapeutics, Inc. | 01 Jun 2021 | 1 | $0 | 4 | Director | 03 Jun 2021, 18:30 |
| LRMR | Larimar Therapeutics, Inc. | 12 May 2021 | 1 | $0 | 4 | Director | 17 May 2021, 17:08 |